XML 16 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Common stock
Retained earnings
Retained earnings
Cumulative Effect, Period of Adoption, Adjustment
Accumulated other comprehensive income (loss)
Accumulated other comprehensive income (loss)
Cumulative Effect, Period of Adoption, Adjustment
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Cumulative effect of adoption of new accounting standards $ 679,723 $ (3,740) $ 300,729 $ 374,673 $ (3,740) $ 4,321 $ 0
Common stock shares outstanding, beginning balance (in shares) at Dec. 31, 2019     23,890,855        
Beginning balance at Dec. 31, 2019 679,723 $ (3,740) $ 300,729 374,673 $ (3,740) 4,321 $ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income 26,043     26,043      
Share-based compensation expense (in shares)     4,944        
Share-based compensation expense 1,184   $ 1,184        
Common stock issued - Option exercise; stock grants (in shares)     116,753        
Common stock issued - Option exercise; stock grants 782   $ 782        
Other comprehensive income 24,189         24,189  
Dividends declared on common stock (7,106)     (7,106)      
Common stock repurchased (in shares)     (1,005,152)        
Common stock repurchased (26,426)   $ (11,824) (14,602)      
Common stock shares outstanding, ending balance (in shares) at Jun. 30, 2020     23,007,400        
Ending balance at Jun. 30, 2020 694,649   $ 290,871 375,268   28,510  
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Cumulative effect of adoption of new accounting standards 677,314   $ 294,302 365,283   17,729  
Common stock shares outstanding, beginning balance (in shares) at Mar. 31, 2020     23,376,793        
Beginning balance at Mar. 31, 2020 677,314   $ 294,302 365,283   17,729  
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income 18,904     18,904      
Share-based compensation expense (in shares)     2,796        
Share-based compensation expense 707   $ 707        
Common stock issued - Option exercise; stock grants (in shares)     29,394        
Common stock issued - Option exercise; stock grants 169   $ 169        
Other comprehensive income 10,781         10,781  
Dividends declared on common stock (3,532)     (3,532)      
Common stock repurchased (in shares)     (401,583)        
Common stock repurchased (9,694)   $ (4,307) (5,387)      
Common stock shares outstanding, ending balance (in shares) at Jun. 30, 2020     23,007,400        
Ending balance at Jun. 30, 2020 694,649   $ 290,871 375,268   28,510  
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Cumulative effect of adoption of new accounting standards 694,649   290,871 375,268   28,510  
Cumulative effect of adoption of new accounting standards $ 717,750   $ 278,505 403,888   35,357  
Common stock shares outstanding, beginning balance (in shares) at Dec. 31, 2020 21,796,904   21,796,904        
Beginning balance at Dec. 31, 2020 $ 717,750   $ 278,505 403,888   35,357  
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income 58,820     58,820      
Share-based compensation expense (in shares)     5,612        
Share-based compensation expense 1,665   $ 1,665        
Common stock issued - Option exercise; stock grants (in shares)     187,753        
Common stock issued - Option exercise; stock grants 2,044   $ 2,044        
Other comprehensive income (7,511)         (7,511)  
Dividends declared on common stock (10,912)     (10,912)      
Common stock repurchased (in shares)     (1,198,610)        
Common stock repurchased $ (53,125)   $ (21,440) (31,685)      
Common stock shares outstanding, ending balance (in shares) at Jun. 30, 2021 20,791,659   20,791,659        
Ending balance at Jun. 30, 2021 $ 708,731   $ 260,774 420,111   27,846  
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Cumulative effect of adoption of new accounting standards 701,463   $ 269,942 411,712   19,809  
Common stock shares outstanding, beginning balance (in shares) at Mar. 31, 2021     21,360,514        
Beginning balance at Mar. 31, 2021 701,463   $ 269,942 411,712   19,809  
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income 29,157     29,157      
Share-based compensation expense (in shares)     2,796        
Share-based compensation expense 855   $ 855        
Common stock issued - Option exercise; stock grants (in shares)     2,312        
Common stock issued - Option exercise; stock grants 195   $ 195        
Other comprehensive income 8,037         8,037  
Dividends declared on common stock (5,378)     (5,378)      
Common stock repurchased (in shares)     (573,963)        
Common stock repurchased $ (25,598)   $ (10,218) (15,380)      
Common stock shares outstanding, ending balance (in shares) at Jun. 30, 2021 20,791,659   20,791,659        
Ending balance at Jun. 30, 2021 $ 708,731   $ 260,774 420,111   27,846  
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Cumulative effect of adoption of new accounting standards $ 708,731   $ 260,774 $ 420,111   $ 27,846